Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | APC inact mut PTEN inact mut |
Therapy | Binimetinib + Dactolisib |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut PTEN inact mut | colorectal cancer | no benefit | Binimetinib + Dactolisib | Preclinical | Actionable | In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338). | 26206338 |
PubMed Id | Reference Title | Details |
---|---|---|
(26206338) | Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer. | Full reference... |